Alnylam Pharmaceuticals
ALNY
#690
Rank
C$52.47 B
Marketcap
C$393.06
Share price
-1.64%
Change (1 day)
-8.11%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): C$5.27

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$5.36. In 2025 the company made an earnings per share (EPS) of C$2.54.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$5.27107.17%
2025C$2.54
2023C-$4.99-62%
2022C-$13.1329.03%
2021C-$10.18-3.36%
2020C-$10.53-8.48%
2019C-$11.517.67%
2018C-$10.6939.74%
2017C-$7.6512.94%
2016C-$6.7738.84%
2015C-$4.88-32.88%
2014C-$7.26259.44%
2013C-$2.02-31.25%
2012C-$2.94

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$9.92 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$3.62-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$60.11 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$11.76-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.03-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.34-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$1.94-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C$0.49-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA